PAHC
Price
$31.78
Change
+$3.26 (+11.43%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
1.21B
91 days until earnings call
Intraday BUY SELL Signals
VTRS
Price
$15.57
Change
-$0.12 (-0.76%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
18.27B
68 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PAHC vs VTRS

Header iconPAHC vs VTRS Comparison
Open Charts PAHC vs VTRSBanner chart's image
PAHC vs VTRS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
PAHC vs. VTRS commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PAHC is a Buy and VTRS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2026
Stock price -- (PAHC: $28.50 vs. VTRS: $15.69)
Brand notoriety: PAHC and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: PAHC: 95% vs. VTRS: 81%
Market capitalization -- PAHC: $1.21B vs. VTRS: $18.27B
PAHC [@Pharmaceuticals: Generic] is valued at $1.21B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $18.27B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PAHC’s FA Score shows that 2 FA rating(s) are green whileVTRS’s FA Score has 3 green FA rating(s).

  • PAHC’s FA Score: 2 green, 3 red.
  • VTRS’s FA Score: 3 green, 2 red.
According to our system of comparison, VTRS is a better buy in the long-term than PAHC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PAHC’s TA Score shows that 4 TA indicator(s) are bullish while VTRS’s TA Score has 3 bullish TA indicator(s).

  • PAHC’s TA Score: 4 bullish, 6 bearish.
  • VTRS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both PAHC and VTRS are a bad buy in the short-term.

Price Growth

PAHC (@Pharmaceuticals: Generic) experienced а -15.39% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was -3.51% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.16%. For the same industry, the average monthly price growth was +24.29%, and the average quarterly price growth was +16.47%.

Reported Earning Dates

PAHC is expected to report earnings on Sep 02, 2026.

VTRS is expected to report earnings on Aug 10, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-2.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($18.3B) has a higher market cap than PAHC($1.21B). VTRS has higher P/E ratio than PAHC: VTRS (236.20) vs PAHC (12.23). VTRS YTD gains are higher at: 28.035 vs. PAHC (-23.553). VTRS has higher annual earnings (EBITDA): 2.47B vs. PAHC (222M). VTRS has more cash in the bank: 406M vs. PAHC (77.5M). PAHC has less debt than VTRS: PAHC (787M) vs VTRS (14.7B). VTRS has higher revenues than PAHC: VTRS (14.6B) vs PAHC (1.5B).
PAHCVTRSPAHC / VTRS
Capitalization1.21B18.3B7%
EBITDA222M2.47B9%
Gain YTD-23.55328.035-84%
P/E Ratio12.23236.205%
Revenue1.5B14.6B10%
Total Cash77.5M406M19%
Total Debt787M14.7B5%
FUNDAMENTALS RATINGS
PAHC vs VTRS: Fundamental Ratings
PAHC
VTRS
OUTLOOK RATING
1..100
5191
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
11
Undervalued
PROFIT vs RISK RATING
1..100
8656
SMR RATING
1..100
3392
PRICE GROWTH RATING
1..100
6617
P/E GROWTH RATING
1..100
961
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (11) in the null industry is in the same range as PAHC (13) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew similarly to PAHC’s over the last 12 months.

VTRS's Profit vs Risk Rating (56) in the null industry is in the same range as PAHC (86) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew similarly to PAHC’s over the last 12 months.

PAHC's SMR Rating (33) in the Pharmaceuticals Major industry is somewhat better than the same rating for VTRS (92) in the null industry. This means that PAHC’s stock grew somewhat faster than VTRS’s over the last 12 months.

VTRS's Price Growth Rating (17) in the null industry is somewhat better than the same rating for PAHC (66) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew somewhat faster than PAHC’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is significantly better than the same rating for PAHC (96) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew significantly faster than PAHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PAHCVTRS
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
65%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
63%
Momentum
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
66%
MACD
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
59%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
61%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
66%
Advances
ODDS (%)
Bullish Trend 29 days ago
74%
Bullish Trend 22 days ago
72%
Declines
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
65%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
55%
Aroon
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
PAHC
Daily Signal:
Gain/Loss:
VTRS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JCNRX30.290.62
+2.09%
Janus Henderson Contrarian R
RICGX69.30N/A
N/A
American Funds Invmt Co of Amer R6
JDVSX16.10N/A
N/A
JPMorgan Diversified I
JGSRX14.68N/A
N/A
JHancock Global Shareholder Yield R2
TMCLX10.31N/A
N/A
Transamerica Energy Infrastructure C

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with ZTS. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then ZTS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
-4.60%
ZTS - PAHC
57%
Loosely correlated
-1.51%
ELAN - PAHC
44%
Loosely correlated
-0.17%
AMRX - PAHC
32%
Poorly correlated
-1.94%
COLL - PAHC
31%
Poorly correlated
-4.15%
VTRS - PAHC
29%
Poorly correlated
-0.76%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with AMRX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
-0.76%
AMRX - VTRS
46%
Loosely correlated
-1.94%
ELAN - VTRS
41%
Loosely correlated
-0.17%
AMPH - VTRS
39%
Loosely correlated
+0.22%
COLL - VTRS
38%
Loosely correlated
-4.15%
ZTS - VTRS
35%
Loosely correlated
-1.51%
More